Flu treatment developer Gemmus Pharma raises Series A round

Flu treatment developer Gemmus Pharma Inc. raised about $1.5 million in a Series A funding led by a syndicate of angel investor groups.

Gemmus, housed in the Mission Bay Innovation Center in the FibroGen building in San Francisco, is targeting a receptor that plays a role in the anti-inflammatory response to viral infections. That approach, the company says, makes it so its treatment isn't susceptible to viral resistance.

The round was led by the Life Science Angels and included BlueTree Allied Angels, Tech Coast Angels, Wilmington Investor Network and The Angels Forum.